Venus Medtech (Hangzhou), Inc. Class H (HK:2500)
:2500
Top Page
Venus Medtech (Hangzhou), Inc. Class H
(2500)
Select Model
Select Model
Rating:53Neutral
Price Target:
HK$3.00
▲(21.95% Upside)
Action:ReiteratedDate:01/17/26
The score is held back primarily by weak fundamentals—ongoing losses and negative free cash flow—despite some balance-sheet strength. Technicals are a meaningful positive with strong trend/momentum, but overbought signals reduce confidence. Valuation remains constrained by negative earnings and the absence of dividend support.
Positive Factors
Relatively strong gross margin
A relatively strong gross margin provides a durable buffer against revenue volatility and supports long-term viability. It signals effective manufacturing and pricing for device products, enabling the company to invest in R&D and clinical studies while absorbing SG&A and pricing pressure in the med-tech sector.
Negative Factors
Persistent net losses and negative margins
Sustained net losses and negative operating margins erode retained earnings and limit internal funding for commercialization and R&D. Over time this constrains strategic choices, increases reliance on external capital, and can weaken negotiating leverage with suppliers and hospital customers.
Read all positive and negative factors
Positive Factors
Negative Factors
Relatively strong gross margin
A relatively strong gross margin provides a durable buffer against revenue volatility and supports long-term viability. It signals effective manufacturing and pricing for device products, enabling the company to invest in R&D and clinical studies while absorbing SG&A and pricing pressure in the med-tech sector.
Read all positive factors
Venus Medtech (Hangzhou), Inc. Class H (2500) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$815.87M
Dividend YieldN/A
Average Volume (3M)2.48M
Price to Earnings (P/E)―
Beta (1Y)0.30
Revenue Growth-8.56%
EPS Growth-14.84%
CountryHK
Employees691
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)N/A
Shares Outstanding441,010,220
10 Day Avg. Volume2,133,843
30 Day Avg. Volume2,483,027
Financial Highlights & Ratios
PEG Ratio-2.60
Price to Book (P/B)1.05
Price to Sales (P/S)4.91
P/FCF Ratio-129.73
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.25
Revenue Forecast (FY)HK$791.75M
Venus Medtech (Hangzhou), Inc. Class H Business Overview & Revenue Model
Company Description
Venus Medtech (Hangzhou) Inc. develops and commercializes transcatheter heart valve medical devices in Mainland China and internationally. The company's products include VenusA-Valve, a transcatheter aortic heart valve replacement (TAVR) product t...
How the Company Makes Money
Venus Medtech generates revenue through the sale of its medical devices, particularly its transcatheter heart valves, to hospitals and healthcare providers. The company operates on a business-to-business model, where it partners with medical insti...
Venus Medtech (Hangzhou), Inc. Class H Financial Statement Overview
Summary
Income Statement
35
Negative
Balance Sheet
55
Neutral
Cash Flow
45
Neutral
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 427.25M | 470.83M | 491.37M | 406.46M | 415.86M | 276.05M |
| Gross Profit | 323.97M | 367.75M | 389.20M | 314.00M | 324.34M | 227.28M |
| EBITDA | -572.39M | -612.96M | -547.84M | -999.37M | -324.03M | -152.83M |
| Net Income | -642.59M | -714.31M | -703.75M | -1.06B | -373.64M | -182.87M |
Balance Sheet | ||||||
| Total Assets | 3.12B | 3.25B | 4.41B | 5.28B | 5.11B | 4.32B |
| Cash, Cash Equivalents and Short-Term Investments | 293.31M | 305.70M | 781.64M | 1.88B | 2.96B | 2.75B |
| Total Debt | 493.59M | 369.09M | 826.19M | 899.64M | 70.78M | 32.76M |
| Total Liabilities | 1.05B | 1.04B | 1.49B | 1.65B | 477.61M | 461.19M |
| Stockholders Equity | 2.07B | 2.21B | 2.92B | 3.61B | 4.55B | 3.82B |
Cash Flow | ||||||
| Free Cash Flow | -56.51M | -17.82M | -872.93M | -908.23M | -602.08M | -361.05M |
| Operating Cash Flow | -58.51M | 23.74M | -610.02M | -729.46M | -456.92M | -237.00M |
| Investing Cash Flow | 17.23M | -19.90M | -346.86M | -1.07B | -653.04M | -297.94M |
| Financing Cash Flow | -149.37M | -487.34M | -173.99M | 635.14M | 1.39B | 927.75M |
Venus Medtech (Hangzhou), Inc. Class H Technical Analysis
Negative
2.46
Price Trends
2.61
Negative
2.54
Negative
2.92
Negative
Market Momentum
-0.22
Positive
32.73
Neutral
20.74
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2500, the sentiment is Negative. The current price of 2.46 is above the 20-day moving average (MA) of 2.12, below the 50-day MA of 2.61, and below the 200-day MA of 2.92, indicating a bearish trend. The MACD of -0.22 indicates Positive momentum. The RSI at 32.73 is Neutral, neither overbought nor oversold. The STOCH value of 20.74 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2500.
Venus Medtech (Hangzhou), Inc. Class H Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | HK$1.80B | 22.44 | 3.90% | ― | 32.93% | ― | |
58 Neutral | HK$8.00B | 13.68 | 4.88% | 0.48% | 35.01% | 483.73% | |
53 Neutral | HK$815.87M | -1.91 | -30.05% | ― | -8.56% | -14.84% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | HK$3.81B | -18.13 | -11.27% | ― | 29.25% | 9.02% | |
43 Neutral | HK$3.44B | -218.71 | 0.22% | ― | -4.38% | ― | |
41 Neutral | HK$650.35M | -4.03 | -9.19% | ― | -30.60% | 28.61% |
* Healthcare Sector Average
HK:2500
Venus Medtech (Hangzhou), Inc. Class H
1.85
-0.56
-23.24%
HK:9996
Peijia Medical Ltd.
5.68
0.48
9.23%
HK:2190
Zylox-Tonbridge Medical Technology Co., Ltd. Class H
23.24
6.66
40.14%
HK:2160
MicroPort CardioFlow Medtech Corp.
2.70
-2.00
-42.55%
HK:2216
Broncus Holding Corp.
1.23
0.18
17.14%
HK:6609
Shanghai Heartcare Medical Technology Corp. Ltd. Class H
46.30
17.45
60.49%
Venus Medtech (Hangzhou), Inc. Class H Corporate Events
Venus Medtech Flags U.S. Patent Suit Over Heart Valve Technology Targeting Edwards Lifesciences
Jan 22, 2026
Venus Medtech (Hangzhou) Inc. has informed shareholders that Cardiovalve Ltd. and MTH IP, L.P. have filed a patent infringement lawsuit in the U.S. District Court for the District of Delaware against Edwards Lifesciences over U.S. Patent No. 10,70...
Venus Medtech Clarifies Position on U.S. Patent Lawsuit and Market Disclosure Obligations
Jan 20, 2026
Venus Medtech (Hangzhou) Inc., a Hong Kong-listed mainland Chinese cardiovascular device developer, operates through entities such as wholly owned subsidiary Cardiovalve Ltd. and joint venture MTH IP, L.P. to advance its portfolio of innovative he...
Venus Medtech to Exit Investee Company with US$15 Million Share Disposal
Dec 29, 2025
Venus Medtech (Hangzhou) Inc. has agreed to dispose of its entire remaining stake in an unnamed investee company, selling approximately 1.05% of the investee’s fully diluted share capital for US$15 million to a wholly owned subsidiary of Bro...
Venus Medtech Files CE MDR Application for Cardiovalve Tricuspid Replacement System
Dec 23, 2025
Venus Medtech (Hangzhou) Inc. has announced that it has formally submitted all application materials for EU CE MDR marking to a European Notified Body for its Cardiovalve transcatheter tricuspid valve replacement system, a key step toward potentia...
Venus Medtech Approves Key Resolution at Extraordinary General Meeting
Nov 28, 2025
Venus Medtech (Hangzhou) Inc. announced that the resolution proposed at their extraordinary general meeting was successfully passed. The resolution involved the approval of terms and transactions under a Disposal Agreement, which was unanimously s...
Venus Medtech Reports Promising Interim Results for Cardiovalve Study
Nov 18, 2025
Venus Medtech has announced interim clinical results from its Cardiovalve Target Study, highlighting the safety and performance of its transcatheter valve replacement system. The study, involving 125 patients across multiple countries, showed prom...
Venus Medtech Announces Convertible Bonds Issuance to Boost Product Development
Nov 14, 2025
Venus Medtech (Hangzhou) Inc. has announced a supplemental agreement regarding the issuance of convertible bonds under a general mandate. The proceeds from this issuance will be used to accelerate the development of the company’s core produc...
Venus Medtech Announces EGM for Disposal Agreement Approval
Nov 12, 2025
Venus Medtech (Hangzhou) Inc. has announced an extraordinary general meeting to be held on November 28, 2025, to approve a Disposal Agreement with Hangzhou Binjiang Urban Construction Development Co., Ltd. This agreement involves the disposal of c...
Venus Medtech Sells Industrial Park Property to Refocus on Core Business
Nov 11, 2025
Venus Medtech has announced a major transaction involving the disposal of property related to its Qiming Healthcare Life Science Industrial Park project, selling it for RMB374,563,969. This move aligns with the company’s strategic shift to c...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.